Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BuSpar Appeal: Bristol Argues Mylan Evaded Waxman/Hatch By Filing Suit

Executive Summary

Mylan attempted to circumvent Waxman/Hatch procedures by filing suit against Bristol-Myers Squibb over its BuSpar (buspirone) metabolite patent before issuing a Paragraph IV certification, Bristol argued before the federal circuit appeals court in Washington D.C. July 12.

You may also be interested in...



BuSpar Generic Decision Favors Bristol: FDA Decision On ANDAs Pending

FDA may consider returning generic buspirone ANDA approvals to tentative approval status as one option in light of an appellate court decision favoring Bristol-Myers Squibb in the BuSpar patent case.

BuSpar Generic Decision Favors Bristol: FDA Decision On ANDAs Pending

FDA may consider returning generic buspirone ANDA approvals to tentative approval status as one option in light of an appellate court decision favoring Bristol-Myers Squibb in the BuSpar patent case.

Bristol BuSpar Pediatric Labeling May Delay Second Round Of Generics

The second round of generic approvals for Bristol's anti-anxiety drug BuSpar (buspirone) appears to be held up by Bristol's attempts to enforce exclusivity based on a change in labeling related to pediatric studies.

Related Content

UsernamePublicRestriction

Register

PS017586

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel